EGFR and glioblastoma: Since both EGFR and its mutant form EGFRvIII have variable expression in GBM, Gressler et al. tested a novel dual‐targeting CAR construct targeted both EGFR and EGFRvIII and showed that NK‐92 cells expressing this CAR have superior antitumor cytotoxicity compared to their single targeting counterpart.81